Cisplatin for Small-Cell Lung Cancer Treatment
Author Information
Author(s): Pujol J-L, Carestia, Daurès J-P
Primary Institution: Institut Universitaire de Recherche Clinique, Montpellier, France
Hypothesis
Does a cisplatin-containing regimen improve survival and response rates in small-cell lung cancer compared to regimens without cisplatin?
Conclusion
Cisplatin-containing regimens lead to higher response rates and better survival probabilities without increasing the risk of toxic death.
Supporting Evidence
- Patients treated with cisplatin had a higher response rate from 62% to 69%.
- Cisplatin reduced the risk of death at 6 months and 1 year.
- The study included 19 trials with a total of 4054 evaluable patients.
Takeaway
Using cisplatin can help patients with small-cell lung cancer respond better to treatment and live longer, without making them more likely to get very sick from the treatment.
Methodology
A meta-analysis of 19 trials comparing cisplatin-containing regimens to those without cisplatin.
Statistical Information
P-Value
P = 0.03, P = 0.002
Confidence Interval
95% CI 1.18–1.55; 95% CI 0.75–0.98; 95% CI 0.69–0.93
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website